Research ArticleAccepted Article
Male Sex Predicts a Favorable Outcome in Early ACPA-negative Rheumatoid Arthritis: Data From An Observational Study.
Giovanni Cagnotto, T.H. Lennart Jacobsson, Emil Rydell, Anna Eberhard, Michele Compagno and Carl Turesson
The Journal of Rheumatology May 2022, jrheum.211199; DOI: https://doi.org/10.3899/jrheum.211199
Giovanni Cagnotto
This work was supported by The Swedish Research Council [grant number 2015-02228], The Swedish Rheumatism Association [grant number R-664091] and Lund University [grant number ALFSKANE-446501]. Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden; Department of Rheumatology, Skane University Hospital, Malmö; Department of Rheumatology and Inflammation Research, Sahlgrenska Acadmy, Gothenburg University, Gothenburg, Sweden. Conflict of interest: G. Cagnotto: no financial disclosures. TH L. Jacobsson: lecture and consulting fees from Novartis, Eli-Lilly and Janssen. E. Rydell: no financial disclosures. A. Eberhard: no financial disclosures. M. Compagno: consulting fees from Abbvie and Sanofi Aventis. C. Turesson: consulting fees from Roche, speaking fees from Abbvie, Bristol Myers-Squibb, Nordic Drugs, Pfizer and Roche, and an unrestricted grant from Bristol Myers-Squibb. Corresponding author: Cagnotto Giovanni, Reumatologimottagning, Jan Waldenströms gata 1b, 20502 Malmö e-mail: Giovanni.cagnotto@med.lu.se
T.H. Lennart Jacobsson
This work was supported by The Swedish Research Council [grant number 2015-02228], The Swedish Rheumatism Association [grant number R-664091] and Lund University [grant number ALFSKANE-446501]. Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden; Department of Rheumatology, Skane University Hospital, Malmö; Department of Rheumatology and Inflammation Research, Sahlgrenska Acadmy, Gothenburg University, Gothenburg, Sweden. Conflict of interest: G. Cagnotto: no financial disclosures. TH L. Jacobsson: lecture and consulting fees from Novartis, Eli-Lilly and Janssen. E. Rydell: no financial disclosures. A. Eberhard: no financial disclosures. M. Compagno: consulting fees from Abbvie and Sanofi Aventis. C. Turesson: consulting fees from Roche, speaking fees from Abbvie, Bristol Myers-Squibb, Nordic Drugs, Pfizer and Roche, and an unrestricted grant from Bristol Myers-Squibb. Corresponding author: Cagnotto Giovanni, Reumatologimottagning, Jan Waldenströms gata 1b, 20502 Malmö e-mail: Giovanni.cagnotto@med.lu.se
Emil Rydell
This work was supported by The Swedish Research Council [grant number 2015-02228], The Swedish Rheumatism Association [grant number R-664091] and Lund University [grant number ALFSKANE-446501]. Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden; Department of Rheumatology, Skane University Hospital, Malmö; Department of Rheumatology and Inflammation Research, Sahlgrenska Acadmy, Gothenburg University, Gothenburg, Sweden. Conflict of interest: G. Cagnotto: no financial disclosures. TH L. Jacobsson: lecture and consulting fees from Novartis, Eli-Lilly and Janssen. E. Rydell: no financial disclosures. A. Eberhard: no financial disclosures. M. Compagno: consulting fees from Abbvie and Sanofi Aventis. C. Turesson: consulting fees from Roche, speaking fees from Abbvie, Bristol Myers-Squibb, Nordic Drugs, Pfizer and Roche, and an unrestricted grant from Bristol Myers-Squibb. Corresponding author: Cagnotto Giovanni, Reumatologimottagning, Jan Waldenströms gata 1b, 20502 Malmö e-mail: Giovanni.cagnotto@med.lu.se
Anna Eberhard
This work was supported by The Swedish Research Council [grant number 2015-02228], The Swedish Rheumatism Association [grant number R-664091] and Lund University [grant number ALFSKANE-446501]. Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden; Department of Rheumatology, Skane University Hospital, Malmö; Department of Rheumatology and Inflammation Research, Sahlgrenska Acadmy, Gothenburg University, Gothenburg, Sweden. Conflict of interest: G. Cagnotto: no financial disclosures. TH L. Jacobsson: lecture and consulting fees from Novartis, Eli-Lilly and Janssen. E. Rydell: no financial disclosures. A. Eberhard: no financial disclosures. M. Compagno: consulting fees from Abbvie and Sanofi Aventis. C. Turesson: consulting fees from Roche, speaking fees from Abbvie, Bristol Myers-Squibb, Nordic Drugs, Pfizer and Roche, and an unrestricted grant from Bristol Myers-Squibb. Corresponding author: Cagnotto Giovanni, Reumatologimottagning, Jan Waldenströms gata 1b, 20502 Malmö e-mail: Giovanni.cagnotto@med.lu.se
Michele Compagno
This work was supported by The Swedish Research Council [grant number 2015-02228], The Swedish Rheumatism Association [grant number R-664091] and Lund University [grant number ALFSKANE-446501]. Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden; Department of Rheumatology, Skane University Hospital, Malmö; Department of Rheumatology and Inflammation Research, Sahlgrenska Acadmy, Gothenburg University, Gothenburg, Sweden. Conflict of interest: G. Cagnotto: no financial disclosures. TH L. Jacobsson: lecture and consulting fees from Novartis, Eli-Lilly and Janssen. E. Rydell: no financial disclosures. A. Eberhard: no financial disclosures. M. Compagno: consulting fees from Abbvie and Sanofi Aventis. C. Turesson: consulting fees from Roche, speaking fees from Abbvie, Bristol Myers-Squibb, Nordic Drugs, Pfizer and Roche, and an unrestricted grant from Bristol Myers-Squibb. Corresponding author: Cagnotto Giovanni, Reumatologimottagning, Jan Waldenströms gata 1b, 20502 Malmö e-mail: Giovanni.cagnotto@med.lu.se
Carl Turesson
This work was supported by The Swedish Research Council [grant number 2015-02228], The Swedish Rheumatism Association [grant number R-664091] and Lund University [grant number ALFSKANE-446501]. Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden; Department of Rheumatology, Skane University Hospital, Malmö; Department of Rheumatology and Inflammation Research, Sahlgrenska Acadmy, Gothenburg University, Gothenburg, Sweden. Conflict of interest: G. Cagnotto: no financial disclosures. TH L. Jacobsson: lecture and consulting fees from Novartis, Eli-Lilly and Janssen. E. Rydell: no financial disclosures. A. Eberhard: no financial disclosures. M. Compagno: consulting fees from Abbvie and Sanofi Aventis. C. Turesson: consulting fees from Roche, speaking fees from Abbvie, Bristol Myers-Squibb, Nordic Drugs, Pfizer and Roche, and an unrestricted grant from Bristol Myers-Squibb. Corresponding author: Cagnotto Giovanni, Reumatologimottagning, Jan Waldenströms gata 1b, 20502 Malmö e-mail: Giovanni.cagnotto@med.lu.se
Article Figures & Data
Additional Files
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Male Sex Predicts a Favorable Outcome in Early ACPA-negative Rheumatoid Arthritis: Data From An Observational Study.
Giovanni Cagnotto, T.H. Lennart Jacobsson, Emil Rydell, Anna Eberhard, Michele Compagno, Carl Turesson
The Journal of Rheumatology May 2022, jrheum.211199; DOI: 10.3899/jrheum.211199
Accepted manuscript
Male Sex Predicts a Favorable Outcome in Early ACPA-negative Rheumatoid Arthritis: Data From An Observational Study.
Giovanni Cagnotto, T.H. Lennart Jacobsson, Emil Rydell, Anna Eberhard, Michele Compagno, Carl Turesson
The Journal of Rheumatology May 2022, jrheum.211199; DOI: 10.3899/jrheum.211199